Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

被引：0
|
作者：
Grob, J. J. [1 ]
Gonzalez Mendoza, R. [2 ]
Basset-Seguin, N. [3 ]
Vornicova, O. [4 ]
Schachter, J. [5 ]
Joshi, A. [6 ]
Meyer, N. [7 ]
Grange, F. [8 ]
Piulats, J. M. [9 ]
Bauman, J. [10 ]
Zhang, P. [11 ]
Gumuscu, B. [11 ]
Swaby, R. F. [11 ]
Hughes, B. G. M. [12 ]
机构：
[1] AIX Marseille Univ, Dermatol, Marseille, France
[2] Ctr Estatal Cancerol Chihuahua, Surg Oncol, Chihuahua, Mexico
[3] Hop St Louis, Dermatol, Paris, France
[4] Rambam Hlth Care Campus, Oncol, Haifa, Israel
[5] Sheba Med Ctr Tel Hashomer, Div Oncol, Ramat Gan, Israel
[6] Townsville Canc Ctr, Med Oncol, Townsville, Qld, Australia
[7] IUCT Oncopole, Med Oncol, Toulouse, France
[8] Hop Robert Debre, CHU Reims, Dermatol Oncol, Reims, France
[9] Hosp Duran & Reinals ICO Hospitalet, Genitourinary Melanoma & Sarcoma Unit, Med Oncol, Barcelona, Spain
[10] Fox Chase Canc Ctr, Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[11] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[12] Univ Queensland, Royal Brisbane & Womens Hosp, Oncol, Brisbane, Qld, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA72
引用
收藏
页码：908 / 908
页数：1
相关论文
共 50 条
  • [31] Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
    Kao, Hsiang-Fong
    Liao, Bin-Chi
    Huang, Yen-Lin
    Huang, Huai-Cheng
    Chen, Chun-Nan
    Chen, Tseng-Cheng
    Hong, Yuan-Jing
    Chan, Ching-Yi
    Chia, Jean-San
    Hong, Ruey-Long
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1560 - 1571
  • [32] Efficacy and safety of pembrolizumab in Chinese patients with recurrent/unresectable/metastatic head and neck squamous cell carcinoma.
    Li, Jieying
    Song, Kai
    Feng, Yuanyong
    Shang, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18001 - E18001
  • [33] POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck
    Forsyth, S.
    Yip, K.
    Foran, B.
    Gougis, P.
    Wheeler, G.
    White, L.
    Chandrakumar, A.
    Blair, K.
    Pathak, Y.
    Spanswick, V.
    Lowe, H.
    Hartley, J.
    Forster, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S686 - S687
  • [34] Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
    Renata Ferrarotto
    Luana G. Sousa
    Yun Qing
    Diana Kaya
    Bettzy Stephen
    Dipti Jain
    Diana Bell
    Shubham Pant
    Apostolia M. Tsimberidou
    Filip Janku
    George Blumenschein
    Bonnie S. Glisson
    Jordi Rodon Ahnert
    Sarina A. Piha-Paul
    J. Jack Lee
    Michael K. Wong
    Charles Lu
    Funda Meric-Bernstam
    Aung Naing
    Advances in Therapy, 2021, 38 : 4581 - 4591
  • [35] Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
    Ferrarotto, Renata
    Sousa, Luana G.
    Qing, Yun
    Kaya, Diana
    Stephen, Bettzy
    Jain, Dipti
    Bell, Diana
    Pant, Shubham
    Tsimberidou, Apostolia M.
    Janku, Filip
    Blumenschein, George
    Glisson, Bonnie S.
    Ahnert, Jordi Rodon
    Piha-Paul, Sarina A.
    Lee, J. Jack
    Wong, Michael K.
    Lu, Charles
    Meric-Bernstam, Funda
    Naing, Aung
    ADVANCES IN THERAPY, 2021, 38 (08) : 4581 - 4591
  • [36] Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
    Strosberg, Jonathan
    Mizuno, Nobumasa
    Doi, Toshihiko
    Grande, Enrique
    Delord, Jean-Pierre
    Shapira-Frommer, Ronnie
    Bergsland, Emily
    Shah, Manisha
    Fakih, Marwan
    Takahashi, Shunji
    Piha-Paul, Sarina A.
    O'Neil, Bert
    Thomas, Sajeve
    Lolkema, Martijn P.
    Chen, Menghui
    Ibrahim, Nageatte
    Norwood, Kevin
    Hadoux, Julien
    CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2124 - 2130
  • [37] Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
    Chung, Hyun Cheol
    Ros, Willeke
    Delord, Jean-Pierre
    Perets, Ruth
    Italiano, Antoine
    Shapira-Frommer, Ronnie
    Manzuk, Lyudmila
    Piha-Paul, Sarina A.
    Xu, Lei
    Zeigenfuss, Susan
    Pruitt, Scott K.
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) : 1470 - +
  • [38] Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
    Kao, Hsiang-fong
    Liao, Bin-Chi
    Huang, Yen-Lin
    Huang, Huai-Cheng
    Chen, Chun-Nan
    Chen, Tseng-Cheng
    Hong, Yuan-Jing
    Chan, Ching-Yi
    Hong, Ruey-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH PITUITARY CARCINOMA: RESULTS FROM A PHASE II STUDY
    Majd, Nazanin
    Waguespack, Steven
    Filip, Janku
    Fu, Siqing
    Penas-Prado, Marta
    Xu, Mingxuan
    Alshawa, Anas
    Kamiya-Matsuoka, Carlos
    Raza, Shaan
    McCutcheon, Ian
    Aung, Naing
    NEURO-ONCOLOGY, 2020, 22 : 39 - 40
  • [40] Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
    Frumovitz, Michael
    Westin, Shannon N.
    Salvo, Gloria
    Zarifa, Abdulrazzak
    Xu, Mingxuan
    Yap, Timothy A.
    Rodon, Ahnert J.
    Karp, Daniel D.
    Abonofal, Abdulrahman
    Jazaeri, Amir A.
    Naing, Aung
    GYNECOLOGIC ONCOLOGY, 2020, 158 (03) : 570 - 575
12345